scholarly journals Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information

2020 ◽  
Vol 13 (12) ◽  
pp. 2032-2037 ◽  
Author(s):  
Xiaoming Qiu ◽  
Hong Wang ◽  
Zhen Wang ◽  
Yufei Fu ◽  
Jianjun Yin
Keyword(s):  
Breast Cancer ◽  
Ki 67 ◽  
Image Information ◽  
Dce Mri ◽  
Cox 2 ◽  
Mri Image

scholarly journals Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer

2017 ◽  
Vol 14 (3) ◽  
pp. 2912-2918 ◽  
Author(s):  
Xiaoming Qiu ◽  
Jixin Mei ◽  
Jianjun Yin ◽  
Hong Wang ◽  
Jinqi Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Correlation Analysis ◽  
Ki 67 ◽  
X Ray ◽  
Cox 2

scholarly journals Associations Between Dynamic Contrast Enhanced Magnetic Resonance Imaging and Clinically Relevant Histopathological Features in Breast Cancer. A Multicenter Analysis

2020 ◽  
Author(s):  
Alexey Surov ◽  
Maciej Pech ◽  
Jin You Kim ◽  
Marco Aiello ◽  
Wei Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Resonance Imaging ◽  
Ki 67 ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

Abstract Background: To provide evident data regarding relationships between quantitative dynamic contrast enhanced magnetic resonance imaging (DCE MRI) and prognostic factors in breast cancer (BC).Methods: Data from 4 centers (200 female patients, mean age, 51.2 ± 11.5 years) were acquired. The following data were collected: histopathological diagnosis, tumor grade, stage, hormone receptor status, KI 67, and DCE MRI values including Ktrans (volume transfer constant), Ve (volume of the extravascular extracellular leakage space (EES) and Kep (diffusion of contrast medium from the EES back to the plasma). DCE MRI values between different groups were compared using the Mann–Whitney U test and by the Kruskal-Wallis H test. The association between DCE MRI and Ki 67 values was calculated by Spearman’s rank correlation coefficient. Results: DCE MRI values of different tumor subtypes overlapped significantly. There were no statistically significant differences of DCE MRI values between different tumor grades. All DCE MRI parameters correlated with KI 67: Ktrans, r = 0.44, p=0.0001; Ve, r = 0.34, p=0.0001; Kep, r = 0.28, p=0.002. ROC analysis identified a Ktrans threshold of 0.3 min-1 for discrimination of tumors with low KI 67 expression (<25%) and high KI 67 expression (≥25%): sensitivity, 75.5%, specificity, 73.0%, accuracy, 74.0%, AUC, 0.78. DCE MRI values overlapped between tumors with different T and N stages.Conclusion: Ktrans, Kep, and Ve cannot be used as reliable a surrogate marker for hormone receptor status, tumor stage and grade in BC. Ktrans may discriminate lesions with high and lower proliferation activity.

scholarly journals Joint Prediction of Breast Cancer Histological Grade and Ki-67 Expression Level Based on DCE-MRI and DWI Radiomics

2020 ◽  
Vol 24 (6) ◽  
pp. 1632-1642 ◽  
Author(s):  
Ming Fan ◽  
Wei Yuan ◽  
Wenrui Zhao ◽  
Maosheng Xu ◽  
Shiwei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Histological Grade ◽  
Expression Level ◽  
Ki 67 ◽  
Dce Mri ◽  
Joint Prediction

Phase II trial of neoadjuvant exemestane [EXE] and celecoxib [CELE] in breast cancer: Results of biomarkers

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11056-11056 ◽  
Author(s):  
C. L. Shapiro ◽  
S. P. Povoski ◽  
R. Jiminez ◽  
J. Dehart ◽  
S. Ottman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Core Biopsy ◽  
Small Sample Size ◽  
Statistical Significance ◽  
Small Sample ◽  
Rank Test ◽  
Ki 67 ◽  
Cancer History ◽  
Cox 2 ◽  
Tumor Measurements

11056 Background: Aromatase [CYP19] activity and expression is increased by prostaglandin E2, thus providing a rational for combining the COX-2 inhibitor, CELE, with an aromatase inhibitor. To evaluate the effects of these drugs on proliferation and other biomarkers, we conducted a neoadjuvant trial of EXE alone followed by the combination of EXE and CELE. The primary endpoint was the assessment of biomarkers and the secondary endpoint was toxicity. Methods: Clinical stages II/III, postmenopausal, estrogen [ER] and/or progesterone receptor [PR] positive, previously untreated, ECOG 0–1 were eligible. Excluded were inflammatory breast cancer, history of myocardial infarction, and documented allergy to aspirin, NSAIDs, or sulfonamides. After initial core biopsy pts received 8 weeks (wks) of EXE 25 mg daily. They then received a second core biopsy followed by 8 wks of EXE and CELE 400 mg twice daily. After 16 wks, pts had definitive surgery. Compliance was assessed by pill counts at study visists every 4 wks. At baseline, 8, and 16 wks, pts had tumor measurements by physical exam, mammogram, and ultrasound. A tissue microarray [TMA] was contructed and immunohistochemical [IHC] staining with commercially available antibodies for Ki-67, COX-2, HER-2, ER, and PR was performed. Two independent pathologists scored intensity and percentage of cells staining and were blinded to treatment and the timimg of specimen acquistion. Statistical analyses were performed using Wilcoxon signed-rank test Results: Twenty pts with a median age 62 (range 56–87) were enrolled. CELE was discontinued in 3 (15%) pts for grade 1 rash-1 pt; grade 1 creatinine elevation-1 pt; and grade 1 melena-1 pt. Three (15%) pts-partial response, 16 (80%)-stable disease, and 1 (5%)-progressive disease. None of the differences in biomarkers between 0 and 8 wks and 8 and 16 wks were significant. A trend toward decreasing mean Ki 67 was observed from 0 to 8 wks (20% vs 9%, p=0.19) and 8 to 16 wks (9% vs 7%, p=0.7) Conclusions: Neoadjuvant EXE followed by EXE/CELE was well tolerated with anti-tumor activity. Tumor cell proliferation decreased by about 50% during EXE, but small sample size precluded reaching statistical significance. Frozen tissue was collected and the results of CYP 19 mRNA expression will be presented. [Table: see text]

Effect of celecoxib, a specific cyclooxygenase 2 inhibitor, on the apoptotic and mitotic indexes of breast cancer in patients with early stage disease

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14132-14132
Author(s):  
A. H. Tfayli ◽  
M. Cherry ◽  
J. Yang ◽  
K. Kojouri ◽  
M. Jafari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Metastatic Breast ◽  
Surgical Excision ◽  
Small Sample ◽  
Matched Pair ◽  
Ki 67 ◽  
Early Stage Disease ◽  
Days Of Therapy ◽  
Cox 2

14132 Background: To assess whether the administration of celecoxib, a specific cyclooxegenease-2 (COX-2) inhibitor, to patients with breast cancer alters the proliferative and apoptotic indexes of their tumors. Methods: Women newly diagnosed with non metastatic breast cancer were enrolled into the study after undergoing a diagnostic core needle biopsy. Patients received celecoxib treatment at 400 mg orally twice a day for 14 days, and then underwent surgical excision of their tumor. Core biopsies obtained at the time of initial diagnostic procedure and surgical excision specimens were stained for Ki-67, as well as COX-2 and cleaved poly (ADP-ribose) polymerase (PARP) expression (as an apoptosis marker). Appropriate negative and positive controls were included. We assessed the difference in Ki- 67, COX-2 and cleaved PARP expression levels, before and after treatment using the Wilcoxon’s matched-pair ranks test and the McNemar’s test. Results: 16 patients were enrolled. The median age was 54.6 years. ER and/or PR expression was present in 81% of tumors; Her-2 neu overexpression was present in 25%. No significant change in COX-2 or cleaved PARP expression was noticed in the post intervention specimen compared to the core biopsies. Surprisingly, there was a significant increase in the Ki-67 expression (p < 0.009). Conclusions: we have conducted a short term prospective study to assess the effects of celecoxib, on the proliferative and apoptotic indexes in patients with early stage breast cancer. We have found an increase in the Ki-67 activity, with no significant down regulation of COX-2 or increase in cleaved PARP expression with 14 days of therapy. This could be partly due to the small sample size. [Table: see text]

scholarly journals Application of MRI Image Based on Computer Semiautomatic Segmentation Algorithm in the Classification Prediction of Breast Cancer Histology

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Aizhu Sheng ◽  
Aijing Li ◽  
Jianbi Xia ◽  
Yizhai Ye
Keyword(s):  
Breast Cancer ◽  
Area Under Curve ◽  
Histological Grade ◽  
Segmentation Algorithm ◽  
Dce Mri ◽  
Gland Area ◽  
Semiautomatic Segmentation ◽  
Auc Value ◽  
Mri Image ◽  
Tumor Area

Objective. The study aimed to investigate the predictive classification accuracy of computer semiautomatic segmentation algorithm for the histological grade of breast tumors through the magnetic resonance imaging (MRI) examination. Methods. Five dynamic contrast-enhanced (DCE) MRI regions of interest (ROIs) were captured using computer semiautomatic segmentation method, referring to the entire tumor area, tumor border area, proximal gland area, middle gland area, and distal gland area. According to the mutual information maximum protocol, the corresponding five ROIs were extracted from diffusion weighted imaging (DWI) combined with DCE-MRI images. To use the features in the nonoverlapping area of DWI image and DCE-MRI image as elements, a single-variable logistic regression model was established corresponding to element characteristics. After multiple training, the model was evaluated using the receiver operating characteristic (ROC) curve and area under curve (AUC). Results. This DCE-MRI combined with DWI was superior to DCE-MRI and DW in the prediction of tumor area features. To use DCE-MRI or DWI alone was less effective than DCE-MRI combined with DWI. The DWI combined DCE-MRI demonstrated good regional segmentation effects in the tumour area, with luminal A value being 0.767 and the area under curve (AUC) value being 0.758. After optimization, the AUC value of the tumor area was 0.929, indicating that classification effects can be enhanced by combining the two imaging methods, which complemented each other. Conclusions. The DWI combined DCE-MRI imaging has improved the early diagnosis effects of breast cancer by predicting the occurrence of breast cancer through the labeling of biomarkers.

Sign in / Sign up

Export Citation Format

Share Document